Genentech · company speakers →
Dr. Ira Mellman will discuss our emerging understanding of how 'checkpoint inhibitors' work, and how this impacts the design and implementation new immunotherapeutic approaches in hematologic and solid tumors. Checkpoint inhibitors have transformed outcomes in several cancers. However deeper understanding of how they work is critical for developing the next generation of immune-based therapies and combinations.
Is this you? Claim this profile →
No public contact links on file.
Sourcing speakers for your event?
Browse the speaker directory →